Taken together, the above findings suggest that GSK3β modulates the competition between CREB and Smad proteins for binding to the shared transcriptional coactivator CBP and that GSK3β inhibition offsets the TGF-β1/Smad signaling activity that drives molecular changes of TEC profibrogenic plasticity in progressive CKD. Here, CREBBP is linked to chronic kidney disease.